Advanced search
Publication Cover
Acta Cardiologica Volume 74, 2019 - Issue 5
Submit an article Journal homepage
205
Views
18
CrossRef citations to date
0
Altmetric
Original Scientific Paper

Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients

Chirik Wah LauDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; View further author information
,
Pieter MartensDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; ;Doctoral School for Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium; Correspondence[email protected]
View further author information
,
Seppe LambeetsDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; View further author information
,
Matthias DupontDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; View further author information
&
Wilfried MullensDepartment of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; ;Faculty of Medicine and Life Sciences, Biomedical Research Institute, Hasselt University, Diepenbeek, BelgiumView further author information
Pages 405-412 | Received 22 Jul 2018, Accepted 04 Sep 2018, Published online: 25 Nov 2018

References

  • McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
  • Lewis EF, Claggett BL, McMurray JJV, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017;10:e003430.
  • Ambrosy AP, Mentz RJ, Fiuzat M, et al. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. Eur J Heart Fail. 2018;20:963–972.
  • Martens P, Belien H, Dupont M, et al. Insights into implementation of sacubitril/valsartan into clinical practice. ESC Heart Fail. 2018;5(3):275–283. doi: 10.1002/ehf2.12258.
  • Martens P, Nijst P, Verbrugge FH, et al. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol. 2018;73:115–123.
  • Martens P, Vercammen J, Ceyssens W, et al. Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure. ESC Heart Fail. 2018;5(4):562-569. doi: 10.1002/ehf2.12248.
  • Martens P, Belien H, Dupont M, et al. The reverse remodelling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018;36:e12435.
  • Packer M, Armstrong WM, Rothstein JM, et al. Sacubitril-valsartan in heart failure: why are more physicians not prescribing it? Ann Intern Med. 2016;165:735–736.
  • Parikh KS, Lippmann SJ, Greiner M, et al. Scope of sacubitril/valsartan eligibility after heart failure hospitalization: findings from the GWTG-HF registry (Get With The Guidelines-Heart Failure). Circulation. 2017;135:2077–2080.
  • Pellicori P, Urbinati A, Shah P, et al. What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? Eur J Heart Fail. 2017;19:768–778.
  • Solomon SD, Claggett B, Packer M, et al. Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC Heart Fail. 2016;4:816–822.
  • Du H, Wonggom P, Tongpeth J, et al. Six-minute walk test for assessing physical functional capacity in chronic heart failure. Curr Heart Fail Rep. 2017;14:158–166.
  • Beltran P, Palau P, Dominguez E, et al. Sacubitril/valsartan and short-term changes in the 6-minute walk test: a pilot study. Int J Cardiol. 2018;252:136–139.
  • van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136:1374–1383.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.